Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Starting soon Not applicable

Hyaluronic Acid and Polynucleotides With Connective Tissue Graft and Coronally Advanced Flap for RT II Gingival Recession

NCT07771244 · tracked via the Priya Life Science Egypt tracker
Phase
Not applicable
Started
2026-09-01
Last updated
2026-08-21

Condition(s) studied

RT II Gingival Recession

Investigational drug(s) / intervention(s)

Coronally Advanced Flap with Connective Tissue Graft and Hyaluronic Acid/Polynucleotides

Coronally Advanced Flap with Connective Tissue Graft and Hyaluronic Acid/Polynucleotides: A coronally advanced flap will be performed with a de-epithelialized connective tissue graft. Approximately 1-2 mL of a hyaluronic acid and polynucleotide mixture will be applied to the graft before suturing

Study summary

This case series will evaluate the effectiveness of injectable hyaluronic acid combined with polynucleotides as an adjunct to coronally advanced flap and connective tissue graft in patients with RT II gingival recession. Twelve patients will be included and followed for 6 months. Clinical outcomes will include percentage of root coverage, clinical attachment level gain, gingival thickness, probing depth, width of keratinized tissue, post-operative pain, and patient aesthetic satisfaction.

Eligibility

Sex
ALL
Min age
15 Years
Max age
60 Years
Healthy volunteers
No
Inclusion Criteria: * Patients with RT II gingival recession. * Age range: 15-60 years. * Systemically healthy patients with no contraindications to surgery. * Patients who have not had previous periodontal surgery in the area of treatment. Exclusion Criteria: * Periodontitis. * Active systemic disease affecting wound healing. * Pregnancy or breastfeeding. * Improperly aligned teeth or teeth with cervical restorations or crowns. * Non-carious cervical lesions

Primary outcome measure(s)

  • Percentage of Root Coverage — Baseline, 1 month, 3 months, and 6 months
    Percentage of root coverage will be calculated using the following formula: (Initial Recession Depth - Post-Treatment Recession Depth) / Initial Recession Depth × 100.
  • Clinical Attachment Level (CAL) Gain — Baseline, 3 months, and 6 months
    Clinical attachment level will be measured in millimetres using a UNC-15 periodontal probe

Trial sites (1)

FacilityCityRegionStatus
Faculty of Dentistry, Cairo University Cairo Egypt
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07771244 on ClinicalTrials.gov ↗ ← All trials in Egypt